The potential use of cannabidiol in the therapy of metabolic syndrome

Kleiner, Dénes; Ditrói, K

doi:10.1556/oh.2012.29308

Cited by 4 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biological mechanism of the ECS could potentially explain this paradox based on the effects of THC and CBD 18 , 50 on the ECS via the CB1 and CB2 receptors. 50 , 51 THC and CBD have been noted to have antiinflammatory effects that can improve MetS, 51 , 52 , 53 characterized as an inflammatory disease. 54 Future studies should explore the impact of dosage, route, and form of cannabis use on the relationship between cannabis use and MetS.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Metabolic Syndrome Among Emerging Adult Cannabis Users by Race/Ethnicity: Analysis of the 2009-2018 National Health and Nutrition Examination Surveys

Baral,

Liu,

Garcia-Davis

et al. 2024

American Journal of Medicine Open

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prevalence of Metabolic Syndrome Among Emerging Adult Cannabis Users by Race/Ethnicity: Analysis of the 2009-2018 National Health and Nutrition Examination Surveys

Baral,

Liu,

Garcia-Davis

et al. 2024

American Journal of Medicine Open

View full text Add to dashboard Cite

“…CBD is known to have effects on metabolism; it may alleviate hyperphagia because of its properties as a CB1 receptor antagonist/inverse agonist and 5HT 1A receptor agonist, and it may also promote the differentiation of adipocytes and act as an immunomodulant [9,10,12,49]. CBD may also help maintain glucose homeostasis by its agonist action on G-protein-coupled receptor (GPR)55; the action may be via insulin secretion in response to glucose concentration in the serum [50].…”

Section: Discussionmentioning

confidence: 99%

Effects of cannabidiol on weight and fasting blood sugar with chronic and subchronic haloperidol administration

et al. 2022

View full text Add to dashboard Cite

Objectives The duration of administration (e.g., subchronic or chronic) of haloperidol may influence its adverse effects. We studied the effects of duration of administration of haloperidol on body weight and fasting blood sugar (FBS). In addition, we examined whether orally administered cannabidiol (CBD) had any putative mitigating influence on haloperidol-induced body weight changes and FBS elevation. Methods Haloperidol (5 mg/kg/day) was administered for 21 days (subchronic administration), via the intraperitoneal (IP) route, or monthly (50 mg/kg monthly) for 3 months (chronic administration), via the intramuscular (IM) route, either alone or before CBD (5 mg/kg/day). Oral CBD (5 mg/kg/day) alone and distilled water alone were administered for 21 days. Weight and FBS were measured before administration of pharmacological agents (distilled water in the control group) and post-administration. Results Group differences in average weight across time were significant. Pairwise comparisons showed that mean weight of the subchronic (IP) haloperidol alone group (Group A) and the chronic (IM) haloperidol before CBD group (Group F) increased significantly over time. Post medications, there was a significant increase in mean FBS in the subchronic (IP) haloperidol group compared to the subchronic (IP) haloperidol before CBD group. There was also a significant reduction in mean FBS from the baseline for the control group only. Conclusion We demonstrated that the duration of administration of haloperidol influenced weight and FBS in rats, suggesting that metabolic side effects, may be influenced by duration of administration. CBD ameliorated the increase in weight and FBS observed in the subchronic (IP) haloperidol groups.

show abstract

“…However, it can only be administered as adjunctive therapy because of its low binding potency, and its inhibitory effect on cytochrome P450 enzymes should also be considered. However, it can be beneficially used in adjuvant therapy due to its few side effects [15].…”

Section: Vol 16 Iss 2 Year 2023 International Journal Of Nutrologymentioning

confidence: 99%

Major approaches to cannabidiol in the treatment of binge eating and obesity: a systematic review

Lacerda

Ribeiro²,

Filho

et al. 2023

IJN

View full text Add to dashboard Cite

Introduction: Obesity represents a multifactorial disease that causes serious public health problems. There are more than 2.50 billion overweight and obese people in the world, and Brazil is in fifth place in the world ranking. In this context, a factor associated with eating disorders is anxiety, which affects 33.7% of the general population. In this sense, cannabidiol (CBD) was identified 50 years ago and has effects that can change mood, sensation, perception, tension, appetite, and pain. Also, CBD showed anxiolytic, antipsychotic, neuroprotective, anti-inflammatory, and antiemetic properties. Objective: It was to analyze, through a systematic review, the main considerations and results in animal and human models of the use of cannabidiol in anxiety and obesity. Methods: The model followed for the systematic review was PRISMA. The search strategy was performed in PubMed, Embase, Ovid and Cochrane Library, Web Of Science, Science Direct Journals (Elsevier), Scopus (Elsevier), and OneFile (Gale) databases. Results: In the context of anxiety and binge eating and the consequent increase in the incidence of obese people, the activation of CB1 receptors improves feeding, modulating the activity of hypothalamic neurons and, subsequently, the release of orexigenic and anorexigenic neuropeptides. Thus, in obesity, the endocannabinoid system (ECS) is generally down-regulated in central and peripheral tissues, as indicated by high and/or overexpression of the CB1 receptor. Therefore, CBD is beneficial for anxiety-related disorders. Thus, CBD has been shown to have anxiolytic, antipsychotic, and neuroprotective properties. Conclusion: Growing evidence indicates that CBD acts as an antipsychotic and anxiolytic, and several reports suggest neuroprotective effects. Furthermore, CBD attenuates the harmful effects of trans-Δ9-tetrahydrocannabinol, both acutely and chronically, including psychotogenic, anxiogenic, and deleterious cognitive effects. This suggests that CBD may improve the disease trajectory of individuals with early psychosis and cannabis misuse in particular.

show abstract

The potential use of cannabidiol in the therapy of metabolic syndrome

Cited by 4 publications

References 40 publications

Prevalence of Metabolic Syndrome Among Emerging Adult Cannabis Users by Race/Ethnicity: Analysis of the 2009-2018 National Health and Nutrition Examination Surveys

Prevalence of Metabolic Syndrome Among Emerging Adult Cannabis Users by Race/Ethnicity: Analysis of the 2009-2018 National Health and Nutrition Examination Surveys

Effects of cannabidiol on weight and fasting blood sugar with chronic and subchronic haloperidol administration

Major approaches to cannabidiol in the treatment of binge eating and obesity: a systematic review

Contact Info

Product

Resources

About